Smallpox (ICD-11: 1E70) - Complete Coding and Diagnostic Guide

1. Introduction

Smallpox represents one of the most significant chapters in the history of world medicine, being a viral infectious disease that profoundly marked humanity until its official eradication declared by the World Health Organization in 1980. Caused by the Variola virus, which has two main variants - Variola major and Variola minor - this exclusively human disease is characterized by distinctive cutaneous manifestations that include progressive maculopapular eruption and formation of vesicles and pustules.

The clinical importance of smallpox transcends its epidemiological history. Although eradicated from natural circulation, knowledge about this condition remains essential for health professionals for several reasons. First, samples of the virus are still maintained in high-security laboratories for scientific research, which theoretically maintains the risk of reemergence, whether through laboratory accident or deliberate use as a biological weapon. Second, smallpox serves as a model for understanding other poxvirus infections that continue to circulate, such as mpox and vaccinia.

From a public health perspective, smallpox demonstrated the capacity of preventive medicine and international cooperation to completely eliminate a disease. This historical achievement established precedents for eradication programs for other diseases. For professionals working with medical coding, epidemiological surveillance, historical research, or preparation for health emergencies, correct coding of smallpox in ICD-11 is fundamental for maintenance of accurate records, retrospective analysis of historical data, and preparation of response protocols for possible future scenarios.

Adequate coding is also critical for global surveillance systems, allowing immediate tracking of any suspected case that may arise, ensuring rapid response from international health authorities.

2. Correct ICD-11 Code

Code: 1E70

Description: Smallpox

Parent category: Poxvirus infections

Official definition: Smallpox is an infectious disease exclusive to humans, caused by one of two variants of the Variola virus, namely Variola major (the more severe form) and Variola minor (the milder form, also known as alastrim). This disease primarily affects the small blood vessels of the skin, oral mucosa, and throat. On the skin, the infectious process results in a characteristic maculopapular rash that progressively evolves into vesicles and subsequently into raised pustules filled with fluid, following a typical distribution pattern.

Code 1E70 is specific for disease caused by Variola virus and should not be confused with other poxvirus infections. The specificity of this code is fundamental to differentiate true smallpox from other conditions caused by related viruses of the same Poxviridae family. The classification in ICD-11 maintains this code for purposes of historical documentation, retrospective research, maintenance of epidemiological surveillance, and preparation for possible future health emergencies.

Although the disease is eradicated, the code remains active and available in international disease classification systems, reflecting the principle that health systems should be prepared for any eventuality and maintain complete and accurate historical records.

3. When to Use This Code

Code 1E70 should be used in specific and well-defined situations, even considering disease eradication. Understanding when to apply this code is essential for healthcare professionals, researchers, and medical coders.

Scenario 1: Laboratory Confirmation of Variola Virus Infection

When a patient presents with acute febrile illness followed by progressive skin eruption and specialized laboratory tests (PCR, viral culture, or electron microscopy) unequivocally confirm the presence of Variola major or Variola minor virus. This scenario would require immediate patient isolation, urgent notification to international health authorities, and activation of public health emergency protocols. Documentation must include specific laboratory results and confirmation by international reference laboratories.

Scenario 2: Review and Coding of Historical Medical Records

Professionals working with digitization and standardization of historical medical records prior to 1980 should use code 1E70 when encountering documented diagnoses of smallpox. This is particularly relevant in historical epidemiological research projects, retrospective public health studies, or when medical institutions are migrating legacy records to modern electronic systems using ICD-11 classification.

Scenario 3: Confirmed Laboratory Exposure

In the event of an accident in one of the two high-security laboratories authorized to maintain samples of Variola virus, if a professional develops compatible symptoms following documented exposure and there is diagnostic confirmation, code 1E70 would be appropriate. This scenario would include detailed documentation of exposure circumstances, incubation period, and complete clinical course.

Scenario 4: Simulations and Emergency Preparedness Exercises

During exercises for bioterrorism preparedness or health emergencies, when health authorities conduct simulations of smallpox outbreaks to test response protocols, code 1E70 may be used in exercise records for training and documentation purposes, always clearly identified as a simulation.

Scenario 5: Scientific Research and Retrospective Studies

Researchers analyzing historical data from smallpox outbreaks, studying the effectiveness of past vaccination programs, or conducting retrospective epidemiological analyses should use code 1E70 for standardization and international comparability of data. This facilitates meta-analyses and comparative studies across different historical periods and geographic regions.

Scenario 6: Highly Substantiated Clinical Suspicion Awaiting Confirmation

In a hypothetical situation where a patient presents with clinical presentation highly suggestive of smallpox (high fever, prostration followed by synchronous, centripetal skin eruption, with characteristic progression from macules to papules, vesicles, and pustules), especially if there is relevant epidemiological history, the code may be used provisionally while awaiting laboratory confirmation, always with immediate notification to competent authorities.

4. When NOT to Use This Code

It is essential to understand the situations where code 1E70 should not be applied, avoiding diagnostic confusion and ensuring accurate coding.

Infections by Other Poxviruses

Code 1E70 should not be used for infections caused by other members of the Poxviridae family. Mpox (formerly known as monkeypox), bovine smallpox, vaccinia, molluscum contagiosum, and other poxvirus infections have their own specific codes. Although they may present superficially similar cutaneous manifestations, they are caused by distinct viruses and require differentiated coding.

Adverse Reactions to Vaccination

Complications or adverse reactions related to smallpox vaccine should not receive code 1E70. These situations include generalized vaccinia, eczema vaccinatum, progressive vaccinia, or other vaccine reactions, which have specific codes in the classification. The distinction is crucial because they represent different pathological processes, despite the relationship with the vaccinia virus used in immunization.

Vesicular Skin Eruptions of Other Etiologies

Various conditions can produce skin eruptions with vesicles or pustules that may be visually confused with smallpox, including varicella (chickenpox), herpes zoster, bullous impetigo, dermatitis herpetiformis, pemphigus, bullous pemphigoid, and other bullous dermatoses. Each of these conditions has a specific code and distinctive characteristics that allow clinical and laboratory differentiation.

Scars or Sequelae of Historical Smallpox

Patients who present with characteristic scars from smallpox contracted in the past (before eradication) should not receive code 1E70 for the current visit, unless they are being specifically evaluated for late complications directly related to the previous infection. Old scars represent sequelae, not active disease.

Unfounded Clinical Suspicion

Cases of nonspecific skin eruptions without distinctive characteristics of smallpox and without plausible epidemiological basis should not receive this code, even provisionally. The extremely low probability of smallpox in the current context requires rigorous criteria before considering this diagnosis.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

Diagnostic confirmation of smallpox requires a systematic and rigorous approach. Clinically, the disease presents an incubation period of approximately seven to seventeen days, followed by a prodromal phase with high fever, intense headache, lower back pain, and prostration. After two to three days, the characteristic skin rash emerges, beginning on the oral mucosa and face, subsequently spreading to the trunk and extremities.

The evolution of skin lesions follows a distinctive pattern: macules evolve to papules, then vesicles and finally pustules, all at the same stage of development simultaneously (synchronous evolution). The distribution is centrifugal, with greater concentration on the extremities and face. The lesions are deep, firm on palpation, and frequently umbilicated.

Laboratory confirmation is absolutely essential and must be performed in maximum biosafety level laboratories. Methods include PCR for detection of viral DNA, electron microscopy for visualization of viral particles, viral culture in specific media, and serological tests for detection of specific antibodies. Samples should be collected from multiple lesions, including vesicular fluid, crusts, and oropharyngeal swabs.

Step 2: Verify Specifiers

Although code 1E70 does not have formal subdivisions in ICD-11, it is important to document specific case characteristics. Severity should be classified considering whether it is Variola major (historically around 30% mortality) or Variola minor (historically less than 1% mortality).

Historical clinical variants include ordinary smallpox (most common form), modified smallpox (in previously vaccinated individuals), flat smallpox (severe form with lesions that do not elevate), hemorrhagic smallpox (rapidly fatal form with hemorrhagic manifestations), and smallpox without rash (extremely rare).

The duration and stage of the disease should be documented: prodromal period, initial eruptive phase, pustular phase, crust formation phase, and desquamation phase. Complications such as encephalitis, secondary pneumonia, sepsis, or disfiguring scars should be coded additionally.

Step 3: Differentiate from Other Codes

1E71 - Mpox: The main difference lies in the etiological agent (mpox virus versus Variola virus) and in subtle clinical characteristics. Mpox typically presents prominent lymphadenopathy (especially cervical, axillary, and inguinal), a characteristic absent or discrete in smallpox. The distribution of lesions may be different, and mpox generally presents less uniform evolution of lesions. Epidemiological history is crucial, including exposure to animals or contact with confirmed mpox cases.

1E72 - Cowpox: Caused by the cowpox virus, this infection typically occurs after direct contact with infected cattle or cats. The lesions are generally localized to the hands and forearms (contact sites), not presenting the systemic dissemination characteristic of smallpox. The systemic presentation is milder, and occupational history or animal exposure is fundamental for differentiation.

1E73 - Vaccinia: This code refers to infections by vaccinia virus, used in the smallpox vaccine. It can occur as a normal vaccine reaction, accidental autoinoculation (transfer of virus from the vaccination site to other areas of the body), or infection in contacts of recently vaccinated individuals. Recent history of smallpox vaccination (personal or close contact) is the essential differentiating element.

Step 4: Necessary Documentation

Adequate documentation for use of code 1E70 should include a comprehensive checklist of information. Essential clinical data include detailed description of symptom chronology, specific characteristics of skin lesions (number, distribution, evolutionary stage, depth), systemic symptoms, and complications.

Laboratory results should specify the diagnostic method used, the laboratory responsible for analysis, date of collection and results, type of sample collected, and confirmation by an international reference laboratory. Critical epidemiological information includes possible sources of exposure, travel history, contacts with suspected or confirmed cases, and occupation or risk activities.

Public health measures implemented should be documented, including patient isolation, contact tracing, notification to competent authorities, and infection control measures. Clinical photographs (respecting privacy protocols) are extremely valuable for documentation and subsequent consultation.

6. Complete Practical Example

Clinical Case:

A 34-year-old research laboratory professional in virology, previously healthy, seeks medical care with a presentation of high fever (39.5°C), intense headache, generalized myalgias, and incapacitating lower back pain with three days of evolution. Reports working in a maximum biological safety laboratory authorized to maintain Variola virus samples for scientific research. Mentions a possible failure in personal protective equipment that occurred twelve days ago.

On the fourth day of symptoms, lesions developed in the oral mucosa, and on the fifth day, erythematous macules appeared on the face and forearms, which rapidly progressed to firm papules. On physical examination on the sixth day, the patient presents febrile, prostrate, with multiple firm papules of 3-5mm, some already evolving to vesicles, distributed predominantly on the face, palms of the hands, and forearms, all apparently at the same stage of development. There is no significant lymphadenopathy.

Maximum security isolation was immediately implemented, international health authorities were notified, and samples were collected from multiple vesicles, oropharyngeal swab, and blood. PCR specific for orthopoxvirus performed in a reference laboratory identified genetic sequences compatible with Variola major virus. Electron microscopy confirmed the presence of viral particles with morphology characteristic of poxvirus. Viral culture in specific medium confirmed growth of Variola virus.

Coding Step by Step:

Criteria Analysis: The case presents all essential diagnostic elements for smallpox: compatible incubation period (twelve days), characteristic prodromal phase (fever, headache, myalgias, lower back pain), cutaneous eruption with typical distribution and evolution (onset in oral mucosa and face, synchronous progression of macules to papules and vesicles), plausible epidemiological history (documented laboratory exposure), and definitive laboratory confirmation by multiple methods.

Code Selected: 1E70 - Smallpox

Complete Justification: Unequivocal laboratory confirmation of Variola major virus infection through specific PCR, electron microscopy, and viral culture constitutes the diagnostic gold standard. The clinical presentation is absolutely compatible with classic smallpox, including chronology, lesion characteristics, and systemic symptoms. The history of laboratory exposure provides plausible epidemiological context for this diagnosis in the post-eradication era.

Complementary Codes: Depending on the evolution, additional codes may be necessary for complications (secondary pneumonia, encephalitis, sepsis) or to document the occupational context of exposure. Codes for external factors related to occupational accidents in laboratories would also be appropriate for complete documentation of the case.

7. Related Codes and Differentiation

Within the Same Category:

1E71 - Mpox

Use 1E71 when there is confirmation of mpox virus infection, characteristically associated with prominent lymphadenopathy, history of exposure to animals (especially African rodents) or contact with confirmed mpox cases. The main difference lies in the etiologic agent and the marked presence of enlarged and painful lymph nodes, a distinctive characteristic that rarely occurs in true smallpox.

1E72 - Bovine Pox

Use 1E72 for confirmed infections by cowpox virus, typically presenting with localized lesions on hands and forearms following direct contact with infected cattle or felines. The main difference is the localized nature of the infection, absence of significant systemic dissemination, and clear history of occupational or recreational animal exposure.

1E73 - Vaccinia

Apply 1E73 for infections or complications related to vaccinia virus, especially in the context of recent smallpox vaccination (own or close contact). The main difference lies in the vaccination history and the generally localized nature or relationship to autoinoculation, although disseminated forms may occur in immunocompromised individuals.

Differential Diagnoses:

Varicella (chickenpox) is distinguished by centripetal distribution (greater concentration on the trunk), asynchronous evolution of lesions (different stages simultaneously) and more superficial lesions. Herpes zoster presents characteristic unilateral dermatomal distribution. Bullous impetigo generally affects children, with superficial lesions that rupture easily. Autoimmune bullous dermatoses present specific histopathologic characteristics and absence of typical viral systemic symptoms.

Epidemiologic history, specific characteristics of lesions, temporal evolution, and laboratory confirmation are key elements for precise distinction between these conditions.

8. Differences with ICD-10

In ICD-10, smallpox was coded as B03, a simple and straightforward code within the chapter of infectious and parasitic diseases. The transition to ICD-11 brought significant structural changes in the organization of codes.

The code 1E70 in ICD-11 maintains specificity for smallpox, but is inserted in a more elaborate hierarchical structure within poxvirus infections. The main conceptual change is clearer integration with other related poxviruses, facilitating navigation between similar conditions and improving the capacity for comparative epidemiological analysis.

ICD-11 offers greater flexibility for adding post-coordinated specifiers, allowing more detailed documentation of clinical features, severity, complications, and epidemiological context without the need for complex multiple codes. This approach improves data granularity without excessively increasing the complexity of basic coding.

Another important difference lies in digital integration: ICD-11 was developed natively as an electronic system, with better support for electronic health record systems, facilitating automated coding and reducing transcription errors. For rare or eradicated conditions such as smallpox, this is particularly relevant for maintaining adequate surveillance.

The practical impact of these changes includes better international traceability of cases (hypothetical or historical), greater ease of integration with global surveillance systems, and enhanced capacity for retrospective analysis of historical data when compared with contemporary information from other poxvirus infections.

9. Frequently Asked Questions

How is smallpox diagnosed?

Smallpox diagnosis requires a combination of detailed clinical evaluation and definitive laboratory confirmation. Clinically, the characteristic pattern of prodromal fever followed by skin eruption with synchronous evolution from macules to papules, vesicles, and pustules is sought, with centrifugal distribution. Laboratorially, PCR is used for detection of viral DNA, electron microscopy for visualization of viral particles, viral culture in maximum biosafety laboratories, and serological tests. Any suspicion of smallpox requires immediate notification to health authorities and sample processing in international reference laboratories with maximum biosafety capacity.

Is treatment available in public health systems?

Historically, there is no widely approved specific antiviral treatment for smallpox, with management being primarily supportive. Some antivirals such as tecovirimat have been developed and approved in some contexts for treatment of orthopoxvirus infections, potentially including smallpox, but their availability is generally restricted to government strategic stockpiles for emergencies. Supportive treatment includes hydration, fever control, pain management, skin lesion care to prevent secondary infections, and respiratory support if necessary. Public health systems in various countries maintain emergency response protocols that would include access to available treatments in case of disease reemergence.

How long does treatment last?

The duration of clinical management of smallpox extends throughout the course of the disease, typically three to four weeks from symptom onset until complete scab separation. The isolation period must be maintained until all scabs have fallen and the skin is completely reepithelized, as the patient remains contagious throughout this entire period. Specific antiviral treatments, when indicated, are generally administered for periods of ten to fourteen days, ideally initiated early in the course of the disease. Post-disease follow-up may be necessary for management of complications and sequelae, including scarring, ophthalmological problems, or neurological complications.

Can this code be used on medical certificates?

Yes, code 1E70 can and should be used on medical certificates when appropriate, although such a situation would be extremely unlikely in the current context. Formal medical documentation, including certificates, should always use standardized international coding to ensure universal understanding and facilitate administrative processes. In the hypothetical case of confirmed smallpox, the medical certificate would be only a small part of the necessary documentation, which would include mandatory notification, reports to international health authorities, and detailed documentation for epidemiological surveillance and public health purposes.

Can smallpox really return after eradication?

Although smallpox has been eradicated from natural circulation, there are theoretical scenarios for reemergence. Samples of the virus are maintained in two maximum biosafety laboratories for scientific research, creating minimal but real risk of accidental release. There is also concern about possible deliberate use as a biological weapon. Additionally, advances in synthetic biology could theoretically allow reconstruction of the virus. For these reasons, international health authorities maintain surveillance, vaccine stockpiles, and emergency response protocols. The scientific community continuously debates the necessity of maintaining viral samples versus destroying them completely.

Who is currently at risk for smallpox?

In the current context, the risk of smallpox is essentially nonexistent for the general population. The only groups with theoretically increased risk are professionals working directly with the virus in authorized laboratories, specialized emergency response teams in bioterrorism, and potentially military personnel in some situations. These groups frequently receive preventive vaccination. The general population faces no significant risk, and mass vaccination programs were discontinued decades ago after eradication, as the risks of the vaccine outweigh the benefits in the absence of viral circulation.

How to differentiate smallpox from other diseases with skin eruptions?

Differentiation is based on specific clinical characteristics and laboratory confirmation. Smallpox presents synchronous evolution of lesions (all at the same stage), centrifugal distribution (greater concentration on extremities and face), deep and firm lesions, often umbilicated, and characteristic prodromal phase. Varicella presents asynchronous evolution, centripetal distribution, and superficial lesions. Mpox presents with prominent lymphadenopathy. Herpes zoster has dermatomal distribution. Drug reactions generally do not present typical viral prodromal phase. Laboratory confirmation through specific PCR and electron microscopy is essential for definitive diagnosis, especially considering the enormous public health implications of a smallpox diagnosis.

Is there a vaccine available against smallpox?

Smallpox vaccines exist and are maintained in strategic stockpiles by various governments and international health organizations. First-generation vaccines (derived from replicating vaccinia virus) were used in the eradication program. Second and third-generation vaccines, which are safer, were developed later. However, routine population vaccination was discontinued after eradication due to vaccine risks outweighing benefits in the absence of viral circulation. Currently, vaccination is reserved for specific high-risk groups, such as researchers working with orthopoxviruses and emergency response teams. In case of disease reemergence, ring vaccination protocols (vaccination of cases, contacts, and contacts of contacts) would be implemented.

Conclusion:

The ICD-11 code 1E70 for smallpox represents more than simple classification of an eradicated disease. It symbolizes the continuous surveillance necessary in public health, the importance of maintaining accurate historical records, and preparation for unlikely but potentially catastrophic scenarios. Health professionals, medical coders, and epidemiological surveillance specialists must understand this code deeply, its appropriate applications, and its distinctions in relation to other poxvirus infections. Accurate coding ensures that global health systems remain prepared, that historical data is properly preserved, and that any future suspected case is identified and managed with the urgency and seriousness the situation would require.

External References

This article was developed based on reliable scientific sources:

References verified on 2026-02-03

Smallpox

Partager